J. Ouyang

发表

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Eiji Higashihara, K. Bae, R. Gansevoort, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

J. Glockner, M. Irazabal, V. Torres, 2011, Kidney international.

Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease

R. Gansevoort, A. Chapman, V. Torres, 2017, The New England journal of medicine.

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

A. Chapman, V. Torres, J. Ouyang, 2017, Journal of clinical pharmacology.

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

R. Gansevoort, A. Chapman, V. Torres, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

R. Gansevoort, A. Chapman, V. Torres, 2016, Clinical journal of the American Society of Nephrology : CJASN.

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

I. Narita, V. Torres, E. Higashihara, 2015, Clinical and Experimental Nephrology.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

E. J. van der Jagt, R. Gansevoort, R. Renken, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Eiji Higashihara, R. Gansevoort, A. Chapman, 2012, The New England journal of medicine.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Christopher M O'Connor, C. O'connor, M. Gheorghiade, 2004, JAMA.

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

K. Swedberg, M. Gheorghiade, F. Zannad, 2009, European heart journal.

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.

K. Swedberg, M. Gheorghiade, F. Zannad, 2013, Journal of cardiac failure.

Oral tolvaptan is safe and effective in chronic hyponatremia.

T. Berl, J. Verbalis, R. Schrier, 2010, Journal of the American Society of Nephrology : JASN.

Vasopressin V 2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Results From a Double-Blind , Randomized Trial

M. Gheorghiade, J. Ouyang, F. Czerwiec, 2003 .

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

C. Correll, J. Ouyang, R. Mcquade, 2015, The American journal of psychiatry.

Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia

E. Weiller, C. Correll, J. Kane, 2016, Schizophrenia Research.

University of Groningen Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

A. Chapman, J. Ouyang, R. Mcquade, 2017 .

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

R. Gansevoort, A. Chapman, V. Torres, 2016, Nephrology, Dialysis and Transplantation.

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

H. Krasa, J. Ouyang, D. Oberdhan, 2022, Kidney international reports.

Estimation of Changes in Kidney Volume Growth Rate in ADPKD

E. Higashihara, J. Ouyang, Jennifer Lee, 2020, Kidney international reports.

Tolvaptan in ADPKD Patients With Very Low Kidney Function

R. Gansevoort, A. Chapman, V. Torres, 2021, Kidney international reports.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

R. Gansevoort, A. Chapman, V. Torres, 2017, Journal of the American Society of Nephrology : JASN.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

R. Gansevoort, A. Chapman, V. Torres, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Multicenter , open-label , extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease TEMPO 4 : 4 Trial Investigators

R. Gansevoort, A. Chapman, V. Torres, 2018 .

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

A. Chapman, R. Perrone, J. Ouyang, 2020, Kidney international reports.

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.

J. Ouyang, O. Sergeyeva, S. Shoaf, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

R. Gansevoort, A. Chapman, V. Torres, 2019, Kidney international.

University of Groningen Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients?

Emilie Cornec-Le Gall, R. Gansevoort, A. Chapman, 2018 .

The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial

R. Gansevoort, A. Chapman, V. Torres, 2021, Journal of the American Society of Nephrology : JASN.

Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures

G. Koch, J. Ouyang, Jennifer Lee, 2019, Journal of biopharmaceutical statistics.

Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination

J. Ouyang, C. Orlandi, M. Konstam, 2002 .

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.

M. Gheorghiade, H. Krasa, J. Ouyang, 2008, Journal of the American College of Cardiology.

Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial

C. O'connor, M. Gheorghiade, K. Adams, 2004 .

Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy

J. Ouyang, C. Orlandi, J. Burnett, 2003 .

Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor Antagonist in Patients with Schizophrenia and Hyponatremia

J. Ouyang, F. Czerwiec, Jennifer Lee, 2008, Biological Psychiatry.

Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.

M. Gheorghiade, J. Ouyang, C. Orlandi, 2006, The American journal of cardiology.

Acute Hemodynamic Effects of Tolvaptan , a Vasopressin V 2 Receptor Blocker , in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International , Multicenter , Randomized , Placebo-Controlled Trial

M. Gheorghiade, H. Krasa, J. Ouyang, 2008 .

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

David D. Shin, D. Lloyd‐Jones, M. Gheorghiade, 2007, Acute cardiac care.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

K. Swedberg, M. Gheorghiade, F. Zannad, 2007, JAMA.

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).

J. Verbalis, H. Krasa, J. Ouyang, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.

J. Ouyang, F. Czerwiec, R. Josiassen, 2012, Clinical schizophrenia & related psychoses.

Overweight and Obesity and Progression of ADPKD

M. Chonchol, Berenice Y. Gitomer, J. Ouyang, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

R. Gansevoort, A. Chapman, M. Irazabal, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

K. Swedberg, M. Gheorghiade, F. Zannad, 2007, JAMA.

University of Groningen Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease

R. Gansevoort, A. Chapman, V. Torres, 2018 .

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

R. Gansevoort, A. Chapman, V. Torres, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

P. Watkins, V. Torres, H. Krasa, 2015, Drug Safety.

Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.

K. Swedberg, M. Gheorghiade, F. Zannad, 2011, American heart journal.

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

J. Ouyang, C. Orlandi, J. Burnett, 2006, American journal of physiology. Renal physiology.

Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial

M. Gheorghiade, J. Ouyang, F. Czerwiec, 2003, Circulation.

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

J. Kane, J. Ouyang, R. Mcquade, 2015, Schizophrenia Research.

Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.

M. Gheorghiade, S. Gottlieb, J. Ouyang, 2006, The American journal of cardiology.

ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL

M. Gheorghiade, K. Adams, R. Benza, 2004 .

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure

K. Swedberg, M. Gheorghiade, F. Zannad, 2007 .

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial

M. Gheorghiade, H. Krasa, J. Ouyang, 2007 .

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

K. Swedberg, M. Vaduganathan, M. Gheorghiade, 2012, Journal of cardiovascular medicine.

Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients

M. Gheorghiade, J. Ouyang, C. Orlandi, 2002 .

Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Christopher Zimmer, Karl Swedberg, Faiez Zannad, 2009, European heart journal.

1069-119 Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF trial

C. O'connor, M. Gheorghiade, K. Adams, 2004 .

Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.

Gerasimos Filippatos, David D Shin, David D. Shin, 2007, Journal of cardiac failure.

OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD

A. Chapman, Berenice Y. Gitomer, R. Perrone, 2023, Kidney international reports.

Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies

E. Weiller, C. Correll, J. Kane, 2016, Schizophrenia Research.

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

A. Chapman, R. Perrone, J. Ouyang, 2020, Kidney international reports.

R. Gansevoort, A. Chapman, V. Torres, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

K. Bae, A. Chapman, V. Torres, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies

E. Weiller, S. Marder, J. Ouyang, 2016, Acta Neuropsychiatrica.

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia

J. Ouyang, A. Forbes, M. Hobart, 2018, The international journal of neuropsychopharmacology.

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial

R. Gansevoort, A. Chapman, M. Irazabal, 2016, Kidney international reports.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

R. Gansevoort, A. Chapman, V. Torres, 2017, American Journal of Nephrology.

Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.

L. Citrome, J. Ouyang, R. Baker, 2019, Journal of clinical psychopharmacology.

Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study

G. Koch, J. Ouyang, K. Carroll, 2017, Pharmaceutical statistics.

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study

E. Weiller, J. Ouyang, R. Mcquade, 2016, The international journal of neuropsychopharmacology.

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study

E. Weiller, C. Correll, J. Kane, 2016, International Journal of Neuropsychopharmacology.

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study

E. Weiller, J. Ouyang, R. Mcquade, 2016, The international journal of neuropsychopharmacology.

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

C. Correll, J. Ouyang, R. Mcquade, 2015, The American journal of psychiatry.

University of Groningen Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease Irazabal,

R. Gansevoort, A. Chapman, M. Irazabal, 2018 .

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

E. J. van der Jagt, R. Gansevoort, R. Renken, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome

M. Irazabal, C. M. Heyer, R. Perrone, 2018 .

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

R. Gansevoort, A. Chapman, M. Irazabal, 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

R. Gansevoort, M. Irazabal, C. M. Heyer, 2018 .

ADPKD - CLINICAL OUTCOME STUDIES

J. Craig, M. Greuter, D. Bolignano, 2014 .